Day: January 5, 2022

BTCS Inc3 Year Market Cap and Price GrowthBTCS IncCrypto Fair Market Value and CashSilver Spring, MD, Jan. 05, 2022 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, has announced the first-ever dividend payable in Bitcoin by a Nasdaq-listed company, which the Company refers to as a Bividend. The Company also published a new investor presentation on its website (www.btcs.com) to provide more insight regarding recent successes and future growth plans, as well as the underlying market dynamics expected to drive BTCS’ growth in 2022. Paramount to the ethos of BTCS are cryptocurrency adoption and financial freedom. Since 2014, BTCS has committed to developing the infrastructure supporting blockchain technology. Continuing this journey, BTCS...

Photo 1BergaCor and BergaCor PlusLAS VEGAS, Jan. 05, 2022 (GLOBE NEWSWIRE) — Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, has received follow-on purchase orders for its exclusive Citrus Bergamot SuperFruit™ from XYMOGEN® and other leading distributors that focus on manufacturing and distributing the highest quality of clinical grade nutraceuticals. “We were able to grow our direct sales business at a fast pace in 2021, despite reduced sales from our wholesale business sector due to COVID,” commented Healthy Extracts president, Duke Pitts. “These follow-on orders indicate the B2B distribution segment is ramping back up in 2022. We also see the potential to introduce some of our other recently launched products through XYMOGEN’s WholeScripts...

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) — Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO, will present a company overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Wednesday, January 12, at 1:30 p.m. EST. The presentation will be webcast live on the Events & Webcasts page on the Investor section of Prometheus’ website and will be available for 30 days following the presentation. It is recommended that users connect to Prometheus’ website several minutes prior to the start of the webcast to ensure a timely connection. About...

WORCESTER, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2022. Details of the events are as follows:11th Annual LifeSci Partners Corporate Access Event: The company will host virtual one-on-one meetings during the conference on Wednesday, January 5 through Friday, January 7, 2022. H.C. Wainwright Virtual BioConnect Conference: The company’s presentation will be available for on-demand viewing on Mustang’s website beginning Monday, January...

Thailand Sites Join Australian Sites Confirmed to Participate in the Study Fremont, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced two clinical sites in Thailand have been selected to participate in the Phase II clinical study of Vitargus®, the first bio-degradable vitreous substitute intended to facilitate retina re-attachment surgery. The new sites, located at the Ramathibodi Hospital at Mahidol University and the Srinagarind Hospital at Khon Kaen University, will join two planned Australian sites already selected to participate in the study. The Company expects the Thailand Food and Drug Administration (“FDA”) and the Australian Therapeutic...

Total hash rate will be increased by 100% to 700GH/s Approximately 350 Ether can be generated per Month by thenHONGKONG, Jan. 05, 2022 (GLOBE NEWSWIRE) — Taoping Inc. (NASDAQ: TAOP, the “Company” or “TAOP”), a provider of blockchain technology and smart cloud services, announced today that it has begun an expansion project of Taoping G Cloud Hong Kong Data Center (the “Center”). The expansion is expected to be completed by the end of January 2022. High-capacity fiber connectivity and world-class infrastructure make Hong Kong a desirable data center location for TAOP. Following the launch of the Center in May 2021, the expansion plan shows the Company’s confidence in developing digital currency business in Hong Kong. The site for this expansion is located in Tsuen Wan, Hong Kong. The Company plans to deploy additional general-purpose...

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. CALGARY, Alberta, Jan. 05, 2022 (GLOBE NEWSWIRE) — Alaris Equity Partners Income Trust (“Alaris” or the “Trust”) (TSX: AD.UN) is pleased to announce the deployment of US$55 million into existing Partners including transactions with Fleet Advantage LLC (“Fleet”), GWM Holdings Inc. and its affiliates (collectively “GWM”) and Body Contour Centers LLC (“BCC”) doing business as Sono Bello. These transactions all closed prior to December 31, 2021. With the transactions announced today, Alaris deployed CDN$359 million in 2021. Unless otherwise stated, all numbers in this press release are presented in US dollars. Fleet The Trust is pleased to announce that it has invested...

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that John T. Burns has been promoted within the Company to Senior Vice President, Finance, and Chief Accounting Officer. “John is an invaluable member of our small, yet nimble SELLAS team. He consistently demonstrates his expertise in accounting and finance, executing upon our business strategy while maintaining the highest degree of fiscal responsibility,” said Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS. “John’s promotion is reflective of his dedication and contributions across finance, accounting, and corporate strategy development...

AUSTIN, TX and DURHAM, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in two virtual investor conferences in January 2022.   Presentation Details Conference: H.C. Wainwright BioConnect 2022 ConferenceFormat: Corporate PresentationPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: January 10, 2022Time: 7:00 a.m. EST Conference: 40th Annual J.P. Morgan Healthcare ConferenceFormat: Corporate PresentationPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate:...